Blog

AHFS Drug Information/Essentials Update – October 2016

The October update to the AHFS Drug Information/Essentials database was published today. Highlights from this month’s update include:

New AHFS/Essentials Monographs

Alectinib (Alecensa®)
Antihemophilic Factor (Recombinant), Porcine Sequence (Obizur®)
Antihemophilic Factor (recombinant), Fc Fusion Protein (Eloctate®)
Asfotase Alfa (Strensiq®)
Atezolizumab (Tecentriq®)
Avanafil (Stendra®)
Brexpiprazole (Rexulti®)
Brivaracetam (Briviact®)
Cariprazine (Vraylar®)
Cholic Acid (Cholbam®)
Coagulation Factor IX (Recombinant, Human) (Idelvion®)
Coagulation Factor X Human (Coagadex®)
Cobicistat (Tybost®, Evotaz®, Prezcobix®, Stribild®)
Daclizumab (Zinbryta®)
Daratumumab (Darzalex®)
Defibrotide Sodium  (Defitelio®)
Deoxycholic Acid (Kybella®)
Dichlorphenamide (Keveyis®)
Eliglustat (Cerdelga®)
Elotuzumab (Empliciti®)
Elvitegravir (Vitekta®)
Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (Genvoya®)
Eteplirsen (Exondys 51®)
Idarucizumab (Praxbind®)
Insulin Degludec (Tresiba®)
Ivabradine Hydrochloride (Corlanor®)
Ixazomib (Ninlaro®)
Ixekizumab (Taltz®)
Lesinurad (Zurampic®)
Lifitegrast (Xiidra®)
Lixisenatide (Adlyxin®)
Lumacaftor and Ivacaftor (Orkambi®)
Mepolizumab (Nucala®)
Metreleptin (Myalept®)
Necitumumab (Portrazza®)
Netupitant and Palonosetron (Akynzeo®)
Obeticholic Acid (Ocaliva®)
Obiltoxaximab (Anthim®)
Osimertinib (Tagrisso®)
Palbociclib (Ibrance®)
Patiromer (Veltassa®)
Pimavanserin (Nuplazid®)
Raxibacumab
Reslizumab (Cinqair®)
Rolapitant (Varubi®)
Sacubitril and Valsartan (Entresto (with valsartan)®)
Sebelipase Alfa (Kanuma®)
Selexipag (Uptravi®)
Sonidegib (Odomzo®)
Sugammadex (Bridion®)
Trabectedin (Yondelis®)
Trifluridine and Tipiracil (Lonsurf®)
Venetoclax (Venclexta®)